Edinburgh Clinical Trials

The Cardiac CARE Trial – Can we prevent heart muscle injury related to chemotherapy?

Cardiac CARE is a randomised open-label label clinical trial for breast cancer and non-Hodgkin lymphoma patients receiving anthracycline adjuvant therapy.

This study tests whether tablet medications called angiotensin receptor blockers (ARB) and B-blockers can prevent heart muscle injury related to chemotherapy in breast cancer and lymphoma patients. We will also show whether a convenient blood test (troponin I) can detect those patients at risk of heart failure.

About the Trial

Cardiac CARE is a non-commercial trial sponsored by a partnership of the University of Edinburgh and NHS Lothian called ACCORD and funded by UK National Institute for Health Research (NIHR) and the British Heart Foundation (BHF).

Get Involved

If you have breast cancer or non-Hodgkin lymphoma and you are planning to start anthracycline adjuvant or neo-adjuvant therapy, and you are aged 18 years or over you may be eligible to take part in the Cardiac CARE trial.

News and Updates

Check here for further information and news about the progress of the Cardiac CARE Trial

Our Centres and Partners

The Cardiac CARE trial is a collaboration of key partners and 8 recruiting centres across the UK.

What is Cardiotoxicity

Cardiotoxicity is when the heart muscle is injured.